Drug Cocktail Slows Progress of Aggressive Breast Cancer
Drug Cocktail Slows Progress of Aggressive Breast Cancer
Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.
Drug Cocktail Slows Progress of Aggressive Breast Cancer
Drug Cocktail Slows Progress of Aggressive Breast Cancer

Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.

Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.

drug development
The UK Pharmaceutical Industry Braces for Brexit
The UK Pharmaceutical Industry Braces for Brexit
Diana Kwon | Oct 12, 2018
As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.
Industry Partners Extensively Involved in Trials They Fund
Industry Partners Extensively Involved in Trials They Fund
Catherine Offord | Oct 5, 2018
A new study suggests that sponsors downplay their influence when reporting trials carried out in collaboration with academic researchers.
Infographic: Treating Duchenne Muscular Dystrophy with CRISPR
Infographic: Treating Duchenne Muscular Dystrophy with CRISPR
Sandeep Ravindran | Aug 30, 2018
The disease is caused by mutations in a single gene. Can gene editing fix the problem?
Gene Editing Could One Day Treat Muscle Disorders
Gene Editing Could One Day Treat Muscle Disorders
Sandeep Ravindran | Aug 30, 2018
Scientists race to develop CRISPR therapies that could save the lives of kids with muscle-wasting conditions.
Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Drug Approval Could Boost Research on Marijuana Treatment for Autism
Drug Approval Could Boost Research on Marijuana Treatment for Autism
Jessica Wright | Aug 17, 2018
Epidiolex, a cannabis-derived medicine for epilepsy, will prompt federal regulatory changes that could crack open access to study the plant.
The NIH Loosens Grip on Gene Therapy Trials
The NIH Loosens Grip on Gene Therapy Trials
Kerry Grens | Aug 16, 2018
The agency proposes ceding its scrutiny of these studies to the FDA.
First RNAi Therapy Approved by FDA
First RNAi Therapy Approved by FDA
Kerry Grens | Aug 10, 2018
Alnylam’s patisiran interferes with the production of a mutated protein present in people with hereditary transthyretin amyloidosis.
Opinion: Learning from Immunotherapy’s Recent Failures
Opinion: Learning from Immunotherapy’s Recent Failures
Luis Felipe Campesato | Aug 1, 2018
The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.